Cellectis (CLLS) Interest & Investment Income (2022 - 2026)
Cellectis (CLLS) recorded quarterly Interest & Investment Income of $11.9 million in Q1 2026, down 15.7% quarter-over-quarter from $14.1 million in Q3 2025, and up 88.84% on a YoY basis from $6.3 million in Q1 2025.
Cellectis (CLLS) Interest & Investment Income (2022 - 2026) Analysis & Trends
Cellectis' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $11.9 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 88.84% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $11.9 million (up 88.84% YoY), while the FY2025 annual figure was $16.1 million, down 63.69% from the prior year.
- Interest & Investment Income was $11.9 million for Q1 2026 at Cellectis, down from $14.1 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $29.7 million in Q3 2024 to a low of $775000.0 in Q1 2023.
- Historically, Interest & Investment Income has averaged $13.3 million across 5 years, with a median of $11.9 million in 2026.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income surged 3694.84% in 2024, then sank 78.59% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $15.2 million in 2022, then tumbled by 64.73% to $5.3 million in 2023, then soared by 456.06% to $29.7 million in 2024, then sank by 52.54% to $14.1 million in 2025, then fell by 15.7% to $11.9 million in 2026.
- The last three Interest & Investment Income figures came in at $11.9 million (Q1 2026), $14.1 million (Q3 2025), and $11.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 597,319.59 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 305,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -14.79 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 11.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.89 Mn |
| Sep 30, 2025 | 14.11 Mn |
| Jun 30, 2025 | 11.58 Mn |
| Mar 31, 2025 | 6.30 Mn |
| Sep 30, 2024 | 29.73 Mn |
| Jun 30, 2024 | 29.41 Mn |
| Mar 31, 2024 | 29.41 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Sep 30, 2023 | 4.92 Mn |
| Mar 31, 2023 | 775,000.00 |
| Sep 30, 2022 | 15.16 Mn |
| Jun 30, 2022 | 12.26 Mn |
| Mar 31, 2022 | 2.27 Mn |